CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma
Top Cited Papers
- 1 January 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 28 (1), e26-e31
- https://doi.org/10.1097/00006676-200401000-00023
Abstract
Recent studies have demonstrated the importance of tumor immunity for a cancer patient's prognosis. In some types of cancer, it has been shown through immunohistochemical analysis that the existence of CD8+ tumor-infiltrating lymphocytes (TILs) is a crucial factor in determining prognosis. In an experimental model, CD4+ lymphocytes together with CD8+ lymphocytes contributed significantly to tumor immunity. Specimens were taken from 80 surgically resected pancreatic adenocarcinomas between 1992 and 1999. Immunohistochemical staining of CD4, CD8, and S100 protein was performed, and the levels of these proteins were determined by microscopic analysis. The percentages of patients in the CD4(+) and CD8(+) groups were 59% (47/80) and 25% (16/80), respectively. When separated into 4 groups, CD4/8(+/+), CD4/8(+/−), CD4/8(−/+) and CD4/8(−/−), the overall survival rate was significantly higher in CD4/8(+/+) patients (13 cases) compared with those in all other groups combined (67 cases; P = 0.0098). CD4/8(+/+) status was negatively correlated with tumor depth and TNM stage. Multivariate analyses showed that CD4/8(+/+) status was an independent favorable prognostic factor. The number of tumor-infiltrating S100 protein positive cells was also significantly higher in the CD4/8(+/+) group than in others (P = 0.0084). In pancreatic adenocarcinoma, the presence of CD4+ TILs together with CD8+ TILs serves as a good indicator of the patient's outcome after surgical treatment.Keywords
This publication has 17 references indexed in Scilit:
- The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunityTrends in Immunology, 2001
- Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic miceInternational Journal of Cancer, 2001
- Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor ImmunityThe Journal of Immunology, 2000
- A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytesEuropean Journal of Immunology, 1999
- Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytesInternational Journal of Cancer, 1999
- Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyteInternational Journal of Cancer, 1999
- Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancerThe Journal of Pathology, 1997
- National Patterns of Care for Pancreatic CancerAnnals of Surgery, 1996
- Long-Term Survival After Curative Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 1996
- Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human CancersArchives of Surgery, 1990